An open-label, multicenter, phase II study of AT-101 in combination with rituximab in patients with untreated, grade I-II, follicular non-Hodgkin's lymphoma.

Trial Profile

An open-label, multicenter, phase II study of AT-101 in combination with rituximab in patients with untreated, grade I-II, follicular non-Hodgkin's lymphoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Aug 2010

At a glance

  • Drugs AT 101; Rituximab
  • Indications Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Sponsors Ascenta Therapeutics
  • Most Recent Events

    • 04 Dec 2008 Planned end date changed from 1 Aug 2008 to 1 Nov 2008, according to ClinicalTrials.gov.
    • 04 Dec 2008 Status changed from active, no longer recruiting to completed,according to ClinicalTrials.gov.
    • 03 May 2008 Status changed from recruiting to in progress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top